Paul G. Kluetz

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

Economics, Econometrics and FinanceMedicineMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 43 papers. Top paper: “FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer”.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0991

N/A

2.9DataRank · unranked

108 citations

Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah +20 more

FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1503

N/A

1.8DataRank · unranked

71 citations

Jeannette Nashed, Diana Bradford, Yi Ren, Sachia G. Khasar, Claudia P. Miller +15 more

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2124

N/A

1.4DataRank · unranked

64 citations

Jamie R. Brewer, Jiaxin Fan, Joyce Cheng, Yuan Li Shen, Yue Xiang +6 more

FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1270

N/A

1.2DataRank · unranked

46 citations

Diana Bradford, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yuan Li Shen, Lingshan Wang +14 more

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1041

N/A

1.1DataRank · unranked

38 citations

M. Naomi Horiba, Mengdie Yuan, Joyce Cheng, Steven J. Lemery, Yuan Li Shen +10 more

US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations

Journal of Clinical Oncology(2024)10.1200/jco.24.00427

N/A

0.978DataRank · unranked

41 citations

James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks +14 more

US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy

Journal of Clinical Oncology(2024)10.1200/jco.24.00546

N/A

0.584DataRank · unranked

15 citations

Diana Bradford, A. K. Sinha, Pallavi S. Mishra‐Kalyani, Catherine C. Lerro, Donna R. Rivera +13 more

Integrating 4 Measures to Evaluate Physical Function in Patients with Cancer (In4M): Protocol for a prospective study

medRxiv(2023)10.1101/2023.03.08.23286924

N/A

0.287DataRank · unranked

4 citations

Paul G. Kluetz, Vishal Bhatnagar, Abbie Brown, Elizabeth Cathcart-Rake, Matthew Diamond +16 more

Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies

BMC Medical Research Methodology(2025)10.1186/s12874-025-02617-y

N/A

0.165DataRank · unranked

2 citations

Vishal Bhatnagar, Brie N. Noble, Tingyu Chen, Mallorie H. Fiero, Ron Hoffman +11 more

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2875

N/A

0DataRank · unranked

231 citations

Sundeep Agrawal, Haley Gittleman, Mallorie H. Fiero, Sriram Subramaniam, Christy S. John +14 more

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4462

N/A

0DataRank · unranked

64 citations

Shan Pradhan, Lola A. Fashoyin‐Aje, Yi Ren, Yuan-Li Shen, Yuan Xu +12 more

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0617

N/A

0DataRank · unranked

10 citations

Sandra J. Casak, Pallavi S. Mishra‐Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur +4 more

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1042

N/A

0DataRank · unranked

21 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Sriram Subramaniam, Hong Zhao +15 more

FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1133

N/A

0DataRank · unranked

9 citations

Christy Osgood, Zhou Feng, Erik Bloomquist, Shenghui Tang, C.J. George Chang +8 more

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Bladder Cancer(2023)10.3233/blc-230056

N/A

0DataRank · unranked

8 citations

Noah M. Hahn, Seth P. Lerner, Jaleh Fallah, Sundeep Agrawal, Ashish M. Kamat +33 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1393

N/A

0DataRank · unranked

32 citations

William F. Maguire, Chana Weinstock, Hui Zhang, Xin Gao, Fang Li +14 more

FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1199

N/A

0DataRank · unranked

27 citations

Brian L. Heiss, Hee‐Koung Joeng, Chana Weinstock, Xin Gao, William F. Pierce +8 more

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0281

N/A

0DataRank · unranked

25 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Brian J. Christmas, Matthew D. Thompson +16 more

FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-2812

N/A

0DataRank · unranked

24 citations

Yuxia Jia, Anurag Sharma, Jiang Hu, Zhenzhen Xu, Daniel L. Suzman +5 more

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0517

N/A

0DataRank · unranked

23 citations

Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup Amatya, Joyce Cheng +9 more

FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0949

N/A

0DataRank · unranked

14 citations

Diana Bradford, Yi Ren, Stephanie Aungst, Claudia P. Miller, Lili Pan +19 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3738

N/A

0DataRank · unranked

18 citations

Daniel Lee, Chana Weinstock, Xin Gao, Catharine C. Bulik, Sundeep Agrawal +9 more

Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3386

N/A

0DataRank · unranked

12 citations

Robert A. Avery, Michael J. Fisher, Roger J. Packer, Karin S. Walsh, Antoinette Y. N. Schouten‐van Meeteren +8 more

Feasibility of structuring electronic health record data to facilitate real‐world data research: ICAREdata methods applied to multicenter cancer clinical trials

Cancer(2024)10.1002/cncr.35528

N/A

0DataRank · unranked

10 citations

Nancy Campbell, Shauna L. Hillman, Elizabeth S. Harlos, David Stein, Miranda Y. Chan +14 more

False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations

JCO Precision Oncology(2024)10.1200/po.24.00354

N/A

0DataRank · unranked

2 citations

Jianjin Xu, Hee‐Koung Joeng, Chana Weinstock, Brian L. Heiss, William F. Maguire +10 more

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1708

N/A

0DataRank · unranked

3 citations

C S Lee, William F. Pierce, Elizabeth Everhart, Adriene King-Ducre, Melanie Royce +13 more

FDA Approval Summary: Afamitresgene Autoleucel for Adults with HLA-Restricted, MAGE-A4–Positive Unresectable or Metastatic Synovial Sarcoma after Prior Chemotherapy

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0595

N/A

0DataRank · unranked

18 citations

Ann Johnson, Asha Das, Ching-Hsien J. Lee, Cong Wang, Xiaofei Wang +4 more

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1388

N/A

0DataRank · unranked

13 citations

Mirat Shah, Lijun Zhang, Joyce Cheng, Mary Kate Bonner, Melissa A. Pegues +22 more

FDA Approval Summary: Vorasidenib for IDH -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1333

N/A

0DataRank · unranked

12 citations

Amy Barone, Stephanie Aungst, Claudia P. Miller, Suryatheja Ananthula, Youwei Bi +20 more

FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1231

N/A

0DataRank · unranked

9 citations

Elaine Chang, Hee‐Koung Joeng, Mallorie H. Fiero, Lingshan Wang, Salaheldin S. Hamed +15 more

Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3357

N/A

0DataRank · unranked

5 citations

Amy Corneli, Pamela Balcazar, Craig Lipset, Sara B. Calvert, Sabrena Mervin-Blake +3 more

FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0688

N/A

0DataRank · unranked

3 citations

Donna R. Rivera, Joseph Wynne, Jian Zhao, Robyn Konicki, Aida Kuzucan +8 more

Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series

The Lancet Haematology(2025)10.1016/s2352-3026(25)00027-4

N/A

0DataRank · unranked

4 citations

Ajay Major, Vishal Bhatnagar, Amylou C. Dueck, Karin E. Smedby, Tarec Christoffer El‐Galaly +8 more

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3652

N/A

0DataRank · unranked

169 citations

Tatiana M. Prowell, Jennifer Gao, Laura L. Fernandes, Emily Li, Xiling Jiang +29 more

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0883

N/A

0DataRank · unranked

0 citations

Dow-Chung Chi, Sundeep Agrawal, Hee‐Koung Joeng, Sarah Kim-McOlash, Wimolnut Manheng +17 more

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium

The Lancet Oncology(2020)10.1016/s1470-2045(19)30790-9

N/A

0DataRank · unranked

311 citations

Madeline Pe, Amylou C. Dueck, Jeff A. Sloan, Ethan Basch, Melanie Calvert +30 more

Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report

The Lancet Oncology(2020)10.1016/s1470-2045(19)30796-x

N/A

0DataRank · unranked

81 citations

Linda Dirven, David Arons, Amanda Bates, Susan M. Chang, Corneel Coens +12 more

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0557

N/A

0DataRank · unranked

180 citations

Leigh Marcus, Lola A. Fashoyin‐Aje, Sirisha L. Mushti, Joyce Cheng, Yuan Li Shen +8 more

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3868

N/A

0DataRank · unranked

89 citations

Suanna S. Bruinooge, Harpreet Singh, Keith D. Wilner, Shadia I. Jalal, Stuart M. Lichtman +12 more

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2334

N/A

0DataRank · unranked

45 citations

Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka +14 more

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Cancer Discovery(2021)10.1158/2159-8290.cd-21-0850

N/A

0DataRank · unranked

32 citations

James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur +2 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4429

N/A

0DataRank · unranked

4 citations

Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani +13 more